Posted by Michael Wonder on 27 Nov 2018
Kyowa Kirin announces Poteligeo receives marketing authorisation in Europe for the treatment of mycosis fungoides and Sézary syndrome
26 November 2018 - Poteligeo will be the first biologic agent targeting CCR4 to be available for patients in Europe.
Kyowa Hakko Kirin Co announces today that it has received a European Commission decision granting a marketing authorisation to Poteligeo (Generic name: mogamulizumab), a humanised monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
MF and SS are the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin's lymphoma.
